Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 3.82 EUR 1.17% Market Closed
Market Cap: 656.9m EUR

Valneva SE
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Valneva SE
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Valneva SE
PAR:VLA
Revenue
€291.4m
CAGR 3-Years
-10%
CAGR 5-Years
19%
CAGR 10-Years
17%
Nanobiotix SA
PAR:NANO
Revenue
-€14m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Revenue
€13.6m
CAGR 3-Years
49%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Revenue
$112.6m
CAGR 3-Years
45%
CAGR 5-Years
-3%
CAGR 10-Years
10%
DBV Technologies SA
PAR:DBV
Revenue
$3.8m
CAGR 3-Years
-27%
CAGR 5-Years
-30%
CAGR 10-Years
-3%
Eurobio Scientific SA
PAR:ALERS
Revenue
€162.1m
CAGR 3-Years
-2%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Valneva SE
Glance View

Market Cap
620.4m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
11.85 EUR
Undervaluation 68%
Intrinsic Value
Price

See Also

What is Valneva SE's Revenue?
Revenue
291.4m EUR

Based on the financial report for Jun 30, 2025, Valneva SE's Revenue amounts to 291.4m EUR.

What is Valneva SE's Revenue growth rate?
Revenue CAGR 10Y
17%

Over the last year, the Revenue growth was 31%. The average annual Revenue growth rates for Valneva SE have been -10% over the past three years , 19% over the past five years , and 17% over the past ten years .

Back to Top